AA
YMAB

AlphaCentric Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

AlphaCentric Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-22,000
Closed -$665K – 242
2021
Q1 		$665K Buy
22,000
+19,000
+633% +$779K 0.22% 35
2020
Q4 		$149K Buy
+3,000
New +$139K 0.06% 84

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AlphaCentric Advisors's YMAB Position: Q2 2021 in Review

AlphaCentric Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q2 2021, closing a stake of 22,000 shares — an estimated $665K sold.

AlphaCentric Advisors first reported a position in YMAB in Q4 2020 and held it in 2 quarters. The position peaked at $665K in Q1 2021. 100 funds tracked by Wall St. Rank hold YMAB as of Q2 2021.

  • AlphaCentric Advisors reported no remaining Y-mAbs Therapeutics position as of Q2 2021 after selling out during the quarter.
  • AlphaCentric Advisors sold 22,000 Y-mAbs Therapeutics shares in Q2 2021, an estimated $665K.
  • AlphaCentric Advisors first reported a position in Y-mAbs Therapeutics in Q4 2020 and held it in 2 quarters.
  • AlphaCentric Advisors's Y-mAbs Therapeutics position peaked at $665K in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2021.

Based on AlphaCentric Advisors's 13F filing for Q2 2021, filed 9 Mar 2022.